SIHUAN PHARM (00460.HK): 6 New Specifications of Collagen Stimulating Filler Approved, Improving Regenerative Aesthetic Medicine Product Matrix

NewTimeSpace · 2026/01/16 13:23 · By Boyuan Chen

SIHUAN PHARM announced that 6 new specifications of its self-developed collagen stimulating filler (poly-L-lactic acid facial filler) under Meiyan Space have been approved for marketing by the National Medical Products Administration (NMPA) of China. These new specifications fill the existing dosage gaps, enhance clinical flexibility and market competitiveness, and help improve the layout of regenerative aesthetic medicine products.

NewTimeSpace News: SIHUAN PHARM (00460.HK) announced on January 16, 2026, that 6 new specifications of the poly-L-lactic acid facial filler independently developed by its subsidiary Meiyan Space Biotechnology Co., Ltd., ranging from 60mg/vial to 130mg/vial, have been officially approved for marketing by China's NMPA. This marks an important upgrade after the product's initial approval.

According to the announcement, the new specifications not only meet the personalized treatment needs of different age groups and aging degrees but also, combined with the product's rapid reconstitution feature, enable doctors to flexibly adjust the dilution concentration and injection dosage, improving treatment efficiency and safety. SIHUAN PHARM stated that it will rely on its channel network covering more than 7,000 medical institutions nationwide to rapidly promote the market launch of the new specifications, driving the aesthetic medicine segment into a new stage of large-scale growth.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

SIHUAN PHARM 00460.HK